東華大學圖書館 |

語系: 繁體中文

說明(常見問題)

回圖書館首頁

手機版館藏查詢

登入

回首頁

切換: 標籤 | MARC模式 | ISBD

Proteinkinase inhibitors

Laufer, Stefan.

FindBook

Google Book

Amazon

博客來

Proteinkinase inhibitors

紀錄類型:	書目-電子資源 : Monograph/item
正題名/作者:	Proteinkinase inhibitors/ edited by Stefan Laufer.
其他作者:	Laufer, Stefan.
出版者:	Cham :Springer International Publishing : : 2021.,
面頁冊數:	vii, 256 p. :ill., digital ;24 cm.
內容註:	ProteinKinase-Inhibitors: A Story of Success -- Function, Structure and Topology of Proteinkinases -- Molecular Modelling -- Case study on Receptor Tyrosine Kinases EGFR, VEGFR, PDGFR -- Achieving high level of selectivity for kinase inhibitors -- Inhibitors of c-Jun N-terminal kinase 3 -- Exploiting kinase inhibitors for cancer treatment - An Overview of Clinical Results and Outlook -- Covalent Janus Kinase 3 Inhibitors.
Contained By:	Springer Nature eBook
標題:	Protein kinases - Inhibitors. -
電子資源:	https://doi.org/10.1007/978-3-030-68180-7
ISBN:	9783030681807

Proteinkinase inhibitors
Proteinkinase inhibitors[electronic resource] /edited by Stefan Laufer. - Cham :Springer International Publishing :2021. - vii, 256 p. :ill., digital ;24 cm. - Topics in medicinal chemistry,361862-2461 ;. - Topics in medicinal chemistry ;36..

ProteinKinase-Inhibitors: A Story of Success -- Function, Structure and Topology of Proteinkinases -- Molecular Modelling -- Case study on Receptor Tyrosine Kinases EGFR, VEGFR, PDGFR -- Achieving high level of selectivity for kinase inhibitors -- Inhibitors of c-Jun N-terminal kinase 3 -- Exploiting kinase inhibitors for cancer treatment - An Overview of Clinical Results and Outlook -- Covalent Janus Kinase 3 Inhibitors.

This book reviews the principles of design and examples of successful implementation of proteinkinase inhibitors (PKI), and offers a comprehensive and authoritative overview of the history and latest developments in the field. Chapters written by experts from industry and academia cover the function, structure and topology of Proteinkinases, molecular modelling, disclose how to achieve high level of selectivity for kinase inhibitors, and exploit kinase inhibitors for cancer treatment. Particular attention is given to Inhibitors of c-Jun N-terminal kinase 3, and to covalent Janus Kinase 3 Inhibitors. A case study on Receptor Tyrosine Kinases EGFR, VEGFR, PDGFR is also presented in this book. Given its breath, this book will appeal to medicinal chemists, students, researchers and professionals alike.

ISBN: 9783030681807

Standard No.: 10.1007/978-3-030-68180-7doiSubjects--Topical Terms:

3460770
Protein kinases
--Inhibitors.

LC Class. No.: QP606.P76

Dewey Class. No.: 572.792

Proteinkinase inhibitors
LDR:02255nmm a2200337 a 4500 001 2238833
003 DE-He213
005 20210702132101.0
006 m d
007 cr nn 008maaau
008 211111s2021 sz s 0 eng d
020 $a 9783030681807 $q (electronic bk.)
020 $a 9783030681791 $q (paper)
024 7 $a 10.1007/978-3-030-68180-7 $2 doi
035 $a 978-3-030-68180-7
040 $a GP $c GP
041 0 $a eng
050 4 $a QP606.P76
072 7 $a PSB $2 bicssc
072 7 $a SCI013020 $2 bisacsh
072 7 $a PSB $2 thema
082 0 4 $a 572.792 $2 23
090 $a QP606.P76 $b P967 2021
245 0 0 $a Proteinkinase inhibitors $h [electronic resource] / $c edited by Stefan Laufer.
260 $a Cham : $b Springer International Publishing : $b Imprint: Springer, $c 2021.
300 $a vii, 256 p. : $b ill., digital ; $c 24 cm.
490 1 $a Topics in medicinal chemistry, $x 1862-2461 ; $v 36
505 0 $a ProteinKinase-Inhibitors: A Story of Success -- Function, Structure and Topology of Proteinkinases -- Molecular Modelling -- Case study on Receptor Tyrosine Kinases EGFR, VEGFR, PDGFR -- Achieving high level of selectivity for kinase inhibitors -- Inhibitors of c-Jun N-terminal kinase 3 -- Exploiting kinase inhibitors for cancer treatment - An Overview of Clinical Results and Outlook -- Covalent Janus Kinase 3 Inhibitors.
520 $a This book reviews the principles of design and examples of successful implementation of proteinkinase inhibitors (PKI), and offers a comprehensive and authoritative overview of the history and latest developments in the field. Chapters written by experts from industry and academia cover the function, structure and topology of Proteinkinases, molecular modelling, disclose how to achieve high level of selectivity for kinase inhibitors, and exploit kinase inhibitors for cancer treatment. Particular attention is given to Inhibitors of c-Jun N-terminal kinase 3, and to covalent Janus Kinase 3 Inhibitors. A case study on Receptor Tyrosine Kinases EGFR, VEGFR, PDGFR is also presented in this book. Given its breath, this book will appeal to medicinal chemists, students, researchers and professionals alike.
650 0 $a Protein kinases $x Inhibitors. $3 3460770
650 0 $a Antineoplastic agents. $3 795427
650 0 $a Pharmaceutical chemistry. $3 550956
650 1 4 $a Medicinal Chemistry. $3 892420
650 2 4 $a Protein Science. $3 1067276
650 2 4 $a Bioorganic Chemistry. $3 899222
650 2 4 $a Pharmaceutical Sciences/Technology. $3 1001579
700 1 $a Laufer, Stefan. $3 3492250
710 2 $a SpringerLink (Online service) $3 836513
773 0 $t Springer Nature eBook
830 0 $a Topics in medicinal chemistry ; $v 36. $3 3492251
856 4 0 $u https://doi.org/10.1007/978-3-030-68180-7
950 $a Chemistry and Materials Science (SpringerNature-11644)